Drug Trial Radar · NCT02364947
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
Last checked: Nov 20, 2026Latest source record: Sep 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
678
Actual
Start
Feb 9, 2015
Primary completion
Jul 30, 2016
Study completion Jul 30, 2016
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- Collaborators
- H. Lundbeck A/S
- First posted
- Feb 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol consumption.
Conditions
- Alcohol Dependence
Interventions
Nalmefene hydrochlorideDrug
As-needed; tablets, orally
PlaceboDrug
As-needed; tablets, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12Time frame: Week 12
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Chubu
Region, Japan
Hokkaido
Region, Japan
Kanto
Region, Japan
Kinki
Region, Japan
Kyusyu
Region, Japan
Tohoku
Region, Japan
Tyugoku
Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.